Novartis division Sandoz announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the marketing authorization of biosimilar infliximab.
Novartis division Sandoz announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the marketing authorization of its biosimilar infliximab.
The positive opinion is based on comprehensive data confirming the biosimilarity of infliximab to the reference product through analytical, preclinical, and clinical data that found the biosimilar matches the reference product in terms of quality, efficacy, and safety. CHMP has recommended the proposed biosimilar for the treatment of all indications of the reference product, including gastroenterology, rheumatology, and dermatology.
“Sandoz is proud to be at the forefront of diversifying the biologics treatment landscape by bringing biosimilar medicines to market for patients living with devastating autoimmune diseases. Today’s positive CHMP opinion marks a strong step forward in our efforts to accelerate patient access to biologics, and specifically infliximab, through our leading portfolio,” said Richard Francis, CEO of Sandoz, in a statement.
In the next step of the biosimilar approval process, the European Commission (EC) will review the CHMP’s positive opinion. The EC has the authority to approve or deny medicines for the European Union. If the EC approves the proposed biosimilar, it will grant a centralized marketing authorization that will be valid in the 28 EU member countries. Norway, Iceland, and Liechtenstein, members of the European Economic Area, will follow corresponding decisions based on the EC’s recommendation.
Sandoz currently has 5 other biosimilars on the European market, including somatropin (sold as Omnitrope), epoetin alfa (sold as Binocrit), filgrastim (sold as Zarzio in Europe), etanercept (sold as Erelzi), and rituximab (sold as Rixathon). In addition, it has another 3 biosimilars in its pipeline: LA-EP2006, a proposed pegfilgrastim biosimilar for the treatment of chemotherapy induced neutropenia; GP2013, a proposed rituximab biosimilar currently approved in the EU and pending an FDA decision for the treatment of certain blood cancers and inflammatory diseases; and GP2017, a proposed adalimumab biosimilar to potentially treat autoimmune diseases, such as rheumatoid arthritis and psoriasis.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.